NASDAQ:COGT Cogent Biosciences (COGT) Stock Price, News & Analysis $7.14 -0.15 (-2.06%) Closing price 04:00 PM EasternExtended Trading$7.14 0.00 (0.00%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Cogent Biosciences Stock (NASDAQ:COGT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cogent Biosciences alerts:Sign Up Key Stats Today's Range$7.07▼$7.5050-Day Range$6.71▼$9.6652-Week Range$5.73▼$12.61Volume633,139 shsAverage Volume1.24 million shsMarket Capitalization$812.89 millionP/E RatioN/ADividend YieldN/APrice Target$14.43Consensus RatingModerate Buy Company OverviewCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Read More… Remove Ads Cogent Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreCOGT MarketRank™: Cogent Biosciences scored higher than 44% of companies evaluated by MarketBeat, and ranked 664th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCogent Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cogent Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cogent Biosciences are expected to grow in the coming year, from ($2.42) to ($2.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cogent Biosciences is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cogent Biosciences is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCogent Biosciences has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cogent Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.22% of the float of Cogent Biosciences has been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Cogent Biosciences has recently increased by 7.96%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCogent Biosciences does not currently pay a dividend.Dividend GrowthCogent Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.22% of the float of Cogent Biosciences has been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Cogent Biosciences has recently increased by 7.96%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.53 News SentimentCogent Biosciences has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Cogent Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for COGT on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cogent Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cogent Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.92% of the stock of Cogent Biosciences is held by insiders.Read more about Cogent Biosciences' insider trading history. Receive COGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address COGT Stock News HeadlinesCogent Biosciences (NASDAQ:COGT) Now Covered by Analysts at ScotiabankMarch 9, 2025 | americanbankingnews.comScotiabank Initiates Coverage of Cogent Biosciences (COGT) with Sector Outperform RecommendationMarch 8, 2025 | msn.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…March 14, 2025 | Crypto Swap Profits (Ad)Piper Sandler Sticks to Their Buy Rating for Cogent Biosciences (COGT)March 7, 2025 | markets.businessinsider.comCogent Biosciences Announces Participation in the Leerink Healthcare ConferenceMarch 7, 2025 | globenewswire.comCogent Biosciences announces expanded results from OLE portion of SUMMIT trialFebruary 27, 2025 | markets.businessinsider.comCogent Biosciences price target lowered to $8 from $10 at BairdFebruary 27, 2025 | markets.businessinsider.comCogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis PatientsFebruary 27, 2025 | globenewswire.comSee More Headlines COGT Stock Analysis - Frequently Asked Questions How have COGT shares performed this year? Cogent Biosciences' stock was trading at $7.80 on January 1st, 2025. Since then, COGT stock has decreased by 8.5% and is now trading at $7.14. View the best growth stocks for 2025 here. How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:COGT) posted its earnings results on Tuesday, November, 12th. The technology company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.07. Who are Cogent Biosciences' major shareholders? Top institutional investors of Cogent Biosciences include FMR LLC (15.00%), Vanguard Group Inc. (5.55%), Point72 Asset Management L.P. (4.84%) and Paradigm Biocapital Advisors LP (4.45%). View institutional ownership trends. How do I buy shares of Cogent Biosciences? Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cogent Biosciences investors own include Visa (V), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/12/2024Today3/14/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COGT CIK1460329 Webwww.cogint.com Phone(617) 945-5576FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$14.43 High Stock Price Target$21.00 Low Stock Price Target$8.00 Potential Upside/Downside+97.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-112.55% Return on Assets-60.44% Debt Debt-to-Equity RatioN/A Current Ratio6.44 Quick Ratio6.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.30 per share Price / Book3.17Miscellaneous Outstanding Shares113,850,000Free Float103,923,000Market Cap$829.97 million OptionableOptionable Beta1.80 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:COGT) was last updated on 3/14/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredOur #1 Defense Stock for MarchChina just deepened its military alliance with America's enemies in the Middle East... By conducting joint ...Behind the Markets | SponsoredElon’s desperate gambleWarning: "DOGE Collapse" Imminent After months of cost-cutting, controversy, and media buzz, DOGE is on the...Altimetry | SponsoredTrump’s new tariffs could break China’s grip on manufacturingLooming trade wars have China scrambling… Over 90% of global corporate executives said they are shutting do...Weiss Ratings | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.